Akari Therapeutics, Plc
AKTX
$1.21
$0.1059.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.29% | 61.70% | -35.79% | -34.51% | -44.13% |
| Total Depreciation and Amortization | -- | -- | -100.00% | 1,200.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 76.27% | -90.36% | 787.64% | 80.86% | -185.64% |
| Change in Net Operating Assets | 14.64% | -34.41% | 28.41% | 727.98% | 258.20% |
| Cash from Operations | -42.55% | 69.55% | -21.02% | 8.28% | -80.03% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -110.34% | -97.10% | -- | -- | -200.00% |
| Total Debt Repaid | -189.58% | -1.51% | -53.95% | -- | -- |
| Issuance of Common Stock | -- | -- | 310.29% | -50.85% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 586.23% | -105.71% | 412.75% | -56.95% | -- |
| Foreign Exchange rate Adjustments | -50.00% | 200.00% | 60.00% | -183.33% | 700.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 121.39% | -167.35% | 213.10% | -186.12% | 63.84% |